A carregar...

DESIGN AND POWERING OF CYSTIC FIBROSIS CLINICAL TRIALS USING PULMONARY EXACERBATION AS AN EFFICACY ENDPOINT

BACKGROUND: Reduction in pulmonary exacerbations is an important efficacy endpoint for CF clinical studies. Powering exacerbation endpoints requires estimation of the future exacerbation incidence in CF study populations, but rates differ across the population. METHODS: We have estimated exacerbatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: VanDevanter, DR, Yegin, A, Morgan, WJ, Millar, SJ, Pasta, DJ, Konstan, MW
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4079110/
https://ncbi.nlm.nih.gov/pubmed/21803665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2011.07.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!